Open AccessRapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
Author(s) -
Lieneke F.M. Ariëns,
Daphne Bakker,
Lotte S Spekhorst,
Jorien van der Schaft,
Judith L. Thijs,
Inge Haeck,
Annebeth E. Flinterman,
Marijke Kamsteeg,
Marie L A Schuttelaar,
Marjolein S. de BruinWeller
Publication year - 2021
Publication title -
acta dermato-venereologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.982
H-Index - 83
eISSN - 1651-2057
pISSN - 0001-5555
DOI - 10.2340/00015555-3886
Subject(s) - presenteeism , dupilumab , atopic dermatitis , medicine , absenteeism , cohort , quality of life (healthcare) , work productivity , cohort study , eczema area and severity index , physical therapy , productivity , dermatology , psychology , nursing , macroeconomics , economics , social psychology
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7–780.8)) to week 52 (€0.0 (0.0–211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice.